Skip to main content
SpringerLink
Log in

Successful treatment with rivaroxaban of an extended superficial vein thrombosis in a patient with acquired antithrombin deficiency due to Peg-asparaginase treatment

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Avramis VI, Sencer S, Periclou A, Sather H, Bostrom BC, Cohen LJ et al (2002) A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 99:1986–1994

    Article  CAS  PubMed  Google Scholar 

  2. Truelove E, Fielding AK, Hunt BJ (2013) The coagulopathy and thrombotic risk associated with l-asparaginase treatment in adults with acute lymphoblastic leukaemia. Leukemia 27(3):553–559

    Article  CAS  PubMed  Google Scholar 

  3. Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Donati MB (2007) Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis. J Thromb Haemost 5:621–623

    Article  CAS  PubMed  Google Scholar 

  4. Grace RF, Dahlberg SE, Neuberg D, Sallan SE, Connors JM, Neufeld EJ et al (2011) The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol 152:452–459

    Article  PubMed  Google Scholar 

  5. Hunault-Berger M, Chevallier P, Delain M, Bulabois CE, Bologna S, Bernard M et al (2008) Changes in antithrombin and fibrinogen levels during induction chemotherapy with l-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica 93(10):1488–1494

    Article  CAS  PubMed  Google Scholar 

  6. Mitchell L, Andrew M, Hanna K, Abshire T, Halton J, Wu J et al (2003) Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 90:235–244

    CAS  PubMed  Google Scholar 

  7. Elhasid R, Lanir N, Sharon R, Weyl Ben Arush M, Levin C, Postovsky S et al (2001) Prophylactic therapy with enoxaparin during l-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis 12:367–370

    Article  CAS  PubMed  Google Scholar 

  8. Kuhle S, Lau A, Bajzar L, Vegh P, Halton J, Cherrick I et al (2006) Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with l-asparaginase: an in vitro study. Br J Haematol 134:526–531

    Article  CAS  PubMed  Google Scholar 

  9. Xarelto. Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf

  10. European Leukemia Net. European Leukemia Trial Registry - Trial: ALL GMALL 07/2003. Available at: http://www.leukemia-net.org/trial/download/public/ALL_GMALL07-03_ShortProtEN.pdf?id=489. Accessed 28 Sept 2006

Download references

Acknowledgments

Judit Skrapits for the performance of coagulation tests in the Central Lab of Markusovszky Hospital.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Hematology, Markusovszky University Teaching Hospital, Markusovszky str 5., 9700, Szombathely, Hungary

    Mark Plander, Tamás Szendrei & János L. Iványi

  2. Hematology and Stem Cell Transplantation, St. István and St. László Hospital, Budapest, Hungary

    Imre Bodó

Authors
  1. Mark Plander
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tamás Szendrei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Imre Bodó
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. János L. Iványi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark Plander.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Plander, M., Szendrei, T., Bodó, I. et al. Successful treatment with rivaroxaban of an extended superficial vein thrombosis in a patient with acquired antithrombin deficiency due to Peg-asparaginase treatment. Ann Hematol 94, 1257–1258 (2015). https://doi.org/10.1007/s00277-015-2368-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-015-2368-1

Keywords

Search

Navigation